BG106151A - Фармацевтичен комплекс - Google Patents

Фармацевтичен комплекс

Info

Publication number
BG106151A
BG106151A BG106151A BG10615101A BG106151A BG 106151 A BG106151 A BG 106151A BG 106151 A BG106151 A BG 106151A BG 10615101 A BG10615101 A BG 10615101A BG 106151 A BG106151 A BG 106151A
Authority
BG
Bulgaria
Prior art keywords
complex
pharmaceutical complex
pharmaceutical
sulphobutylether
eletriptan
Prior art date
Application number
BG106151A
Other languages
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG106151A publication Critical patent/BG106151A/bg

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретението се отнася до комплекс на елетриптани сулфобутилетер-бета-циклодекстрин или негова фармацевтично приемлива сол, до методи за получаването му, до фармацевтичен състав, който го съдържа, както и до използването на комплекса.
BG106151A 1999-06-29 2001-11-26 Фармацевтичен комплекс BG106151A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
BG106151A true BG106151A (bg) 2002-05-31

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106151A BG106151A (bg) 1999-06-29 2001-11-26 Фармацевтичен комплекс

Country Status (44)

Country Link
US (2) US6713461B1 (bg)
EP (1) EP1189640B1 (bg)
JP (2) JP4454900B2 (bg)
KR (1) KR20020015067A (bg)
CN (1) CN1198654C (bg)
AP (1) AP2001002369A0 (bg)
AR (1) AR033337A1 (bg)
AT (1) ATE290884T1 (bg)
AU (1) AU770169B2 (bg)
BG (1) BG106151A (bg)
BR (1) BR0011845A (bg)
CA (1) CA2376847C (bg)
CO (1) CO5170494A1 (bg)
CZ (1) CZ20014572A3 (bg)
DE (1) DE60018744T2 (bg)
DZ (1) DZ3320A1 (bg)
EA (1) EA003908B1 (bg)
EC (1) ECSP003551A (bg)
EE (1) EE200100697A (bg)
ES (1) ES2235879T3 (bg)
GB (1) GB9915231D0 (bg)
GE (1) GEP20043377B (bg)
GT (1) GT200000102A (bg)
HR (1) HRP20010951A2 (bg)
HU (1) HUP0201629A3 (bg)
IL (1) IL146341A0 (bg)
IS (1) IS6163A (bg)
MA (1) MA26801A1 (bg)
MX (1) MXPA01013274A (bg)
NO (1) NO20016430L (bg)
NZ (1) NZ515235A (bg)
OA (1) OA11964A (bg)
PA (1) PA8496801A1 (bg)
PE (1) PE20010346A1 (bg)
PL (1) PL352902A1 (bg)
SK (1) SK18932001A3 (bg)
SV (1) SV2002000112A (bg)
TN (1) TNSN00142A1 (bg)
TR (1) TR200103827T2 (bg)
UA (1) UA66932C2 (bg)
UY (1) UY26224A1 (bg)
WO (1) WO2001000243A1 (bg)
YU (1) YU87501A (bg)
ZA (1) ZA200110454B (bg)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
WO2019143925A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
HU212730B (en) 1990-03-28 1996-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusion complexes of cyclodextrine or its derivative and 3-morpholino-sydnonimine or its salt or its tautomer and pharmaceutical compositions containing them
AU651637B2 (en) 1990-10-15 1994-07-28 Pfizer Inc. Indole derivatives
US5665767A (en) 1993-03-05 1997-09-09 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
EP1024833A1 (en) 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
WO1999001135A1 (en) 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
AU770169B2 (en) 2004-02-12
AP2001002369A0 (en) 2001-12-31
SV2002000112A (es) 2002-02-05
IS6163A (is) 2001-11-16
NO20016430L (no) 2002-02-26
DE60018744D1 (de) 2005-04-21
CZ20014572A3 (cs) 2002-08-14
AR033337A1 (es) 2003-12-17
EA200101106A1 (ru) 2002-06-27
DZ3320A1 (fr) 2001-01-04
JP2003503364A (ja) 2003-01-28
PL352902A1 (en) 2003-09-22
US20040186076A1 (en) 2004-09-23
JP2006257091A (ja) 2006-09-28
NZ515235A (en) 2003-08-29
PE20010346A1 (es) 2001-03-26
IL146341A0 (en) 2002-07-25
EA003908B1 (ru) 2003-10-30
EP1189640B1 (en) 2005-03-16
ATE290884T1 (de) 2005-04-15
PA8496801A1 (es) 2002-02-21
KR20020015067A (ko) 2002-02-27
OA11964A (en) 2006-04-17
HRP20010951A2 (en) 2005-04-30
CA2376847A1 (en) 2001-01-04
MXPA01013274A (es) 2002-06-04
DE60018744T2 (de) 2006-05-18
EP1189640A1 (en) 2002-03-27
CN1359303A (zh) 2002-07-17
UY26224A1 (es) 2001-01-31
AU4774100A (en) 2001-01-31
UA66932C2 (en) 2004-06-15
GB9915231D0 (en) 1999-09-01
YU87501A (sh) 2004-05-12
HUP0201629A3 (en) 2003-11-28
ECSP003551A (es) 2002-01-25
TNSN00142A1 (fr) 2005-11-10
SK18932001A3 (sk) 2002-09-10
WO2001000243A1 (en) 2001-01-04
TR200103827T2 (tr) 2002-05-21
NO20016430D0 (no) 2001-12-28
CN1198654C (zh) 2005-04-27
ES2235879T3 (es) 2005-07-16
US6713461B1 (en) 2004-03-30
BR0011845A (pt) 2002-03-05
JP4454900B2 (ja) 2010-04-21
EE200100697A (et) 2003-02-17
MA26801A1 (fr) 2004-12-20
CA2376847C (en) 2007-09-25
ZA200110454B (en) 2002-12-20
CO5170494A1 (es) 2002-06-27
GT200000102A (es) 2001-12-14
GEP20043377B (en) 2004-04-13
HUP0201629A2 (hu) 2003-03-28

Similar Documents

Publication Publication Date Title
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
MY125978A (en) Admantane derivatives
AP9801392A0 (en) Concentrated antibody preparation.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HK1028594A1 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
BG105459A (bg) Фармацевтична форма съдържаща моксифлоксацин
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
HK1048986B (zh) 2'-取代的1，1'-聯苯-2-甲酰胺、它們的製備方法、作為藥物的用途和含有它們的藥物製劑
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
HUP9903353A3 (en) 7alpha-(methyl-amino-pentyl)-estratrienes, pharmaceutical preparations which contain said 7alpha-(5-methylaminopentyl) -estratrienes and use thereof for production of drugs
GEP20063719B (en) Prevention of Migraine Recurrence
BG104179A (bg) Използване на фанхинон за лечението на болестта на алцхаймер
BG106151A (bg) Фармацевтичен комплекс
GB9907571D0 (en) Compounds
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
BG106534A (bg) Разтвор за перорално приложение, съдържащ галантамин и подсладител
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
AP9901472A0 (en) Crystalline pharmaceutical product.
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT